Table 1 Baseline and clinical characteristics of the thyroid dose-volume constraint versus the non-restricted groups
Variables | Thyroid dose-volume constraint | P value | |
|---|---|---|---|
Yes (N = 46) | No (N = 46) | ||
Male [n (%)] | 34 (73.9) | 34 (73.9) | 1.000 |
Age (years, mean ± SD) | 46.43 ± 7.85 | 47.24 ± 9.65 | 0.662 |
T stage [n (%)] | 0.652 | ||
T0 | 2 (4.3) | 0 (0.0) | |
T1 | 15 (32.6) | 14 (30.4) | |
T2 | 8 (17.4) | 7 (15.2) | |
T3 | 14 (30.4) | 17 (37.0) | |
T4 | 7 (15.2) | 8 (17.4) | |
N stage [n (%)] | 0.705 | ||
N0 | 6 (13.0) | 4 (8.7) | |
N1 | 18 (39.1) | 23 (50.0) | |
N2 | 13 (28.3) | 10 (21.7) | |
N3 | 9 (19.6) | 9 (19.6) | |
FT3 on admission (pmol/L, mean ± SD) | 5.45 ± 0.62 | 5.32 ± 0.58 | 0.315 |
FT4 on admission [pmol/L, M (IQR)] | 11.46 (10.40–12.68) | 11.04 (10.52–12.00) | 0.870 |
TSH on admission [mIU/L, M (IQR)] | 1.37 (0.54–4.30) | 1.48 (1.12–3.13) | 0.472 |
Thyroid volume before radiotherapy [cc, M (IQR)] | 13.91 (11.29–17.58) | 13.20 (11.26–16.23) | 0.437 |
PTV coverage [%, M (IQR)] | 98.4 (97.9–98.95) | 98.6 (97.85–98.95) | 0.841 |
Mean dose received by spinal cord (Gy, mean ± SD) | 39.6 ± 1.28 | 40.38 ± 0.63 | 0.306 |
Mean dose received by esophagus (Gy, mean ± SD) | 38.54 ± 3.11 | 41.48 ± 4.65 | 0.322 |
No | 14 (30.4) | 13 (28.3) | |
Concurrent chemoradiotherapy [n (%)] | 0.815 | ||
Yes | 14 (32.6) | 14 (30.4) | |
No | 29 (66.7) | 29 (69.0) | |
Adjuvant chemotherapy [n (%)] | 0.335 | ||
Yes | 4 (8.7) | 7 (15.2) | |
No | 42 (91.3) | 39 (84.8) | |
Radiotherapy technology [n (%)] | 0.404 | ||
VMAT | 21 (45.7) | 25 (54.3) | |
TOMO | 25 (54.3) | 21 (45.7) | |
Targeted therapy | 0.877 | ||
Yes | 25 (58.1) | 26 (56.5) | |
No | 18 (41.9) | 20 (43.5) | |